Seroatlas · Human Serome Atlas

SLITRK3

SLIT and NTRK-like protein 3

Also known as: KIAA0848, SLIK3_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: O94933
Gene: SLITRK3
Ensembl: ENSG00000121871
Chromosome: 3
Canonical length: 977 aa
Protein class: Predicted intracellular proteins, Predicted membrane proteins
Subcellular location: Mitochondria

OverviewNCBI Gene

This gene encodes a member of the Slitrk family of structurally related transmembrane proteins that are involved in controlling neurite outgrowth. The encoded protein contains two leucine-rich repeat (LRR) domains and a C-terminal domain that is partially similar to Trk neurotrophin receptor protein. Enhanced expression of this gene was found in tissue from several different types of tumors. Alternative splicing results in multiple transcript variants, all encoding the same protein. [provided by RefSeq, Jan 2016]

Canonical amino-acid sequenceUniProt

977 residues, UniProt reviewed canonical sequence.

>O94933|SLITRK3
     1  MKPSIAEMLH RGRMLWIILL STIALGWTTP IPLIEDSEEI DEPCFDPCYC EVKESLFHIH
    61  CDSKGFTNIS QITEFWSRPF KLYLQRNSMR KLYTNSFLHL NNAVSINLGN NALQDIQTGA
   121  FNGLKILKRL YLHENKLDVF RNDTFLGLES LEYLQADYNV IKRIESGAFR NLSKLRVLIL
   181  NDNLIPMLPT NLFKAVSLTH LDLRGNRLKV LFYRGMLDHI GRSLMELQLE ENPWNCTCEI
   241  VQLKSWLERI PYTALVGDIT CETPFHFHGK DLREIRKTEL CPLLSDSEVE ASLGIPHSSS
   301  SKENAWPTKP SSMLSSVHFT ASSVEYKSSN KQPKPTKQPR TPRPPSTSQA LYPGPNQPPI
   361  APYQTRPPIP IICPTGCTCN LHINDLGLTV NCKERGFNNI SELLPRPLNA KKLYLSSNLI
   421  QKIYRSDFWN FSSLDLLHLG NNRISYVQDG AFINLPNLKS LFLNGNDIEK LTPGMFRGLQ
   481  SLHYLYFEFN VIREIQPAAF SLMPNLKLLF LNNNLLRTLP TDAFAGTSLA RLNLRKNYFL
   541  YLPVAGVLEH LNAIVQIDLN ENPWDCTCDL VPFKQWIETI SSVSVVGDVL CRSPENLTHR
   601  DVRTIELEVL CPEMLHVAPA GESPAQPGDS HLIGAPTSAS PYEFSPPGGP VPLSVLILSL
   661  LVLFFSAVFV AAGLFAYVLR RRRKKLPFRS KRQEGVDLTG IQMQCHRLFE DGGGGGGGSG
   721  GGGRPTLSSP EKAPPVGHVY EYIPHPVTQM CNNPIYKPRE EEEVAVSSAQ EAGSAERGGP
   781  GTQPPGMGEA LLGSEQFAET PKENHSNYRT LLEKEKEWAL AVSSSQLNTI VTVNHHHPHH
   841  PAVGGVSGVV GGTGGDLAGF RHHEKNGGVV LFPPGGGCGS GSMLLDRERP QPAPCTVGFV
   901  DCLYGTVPKL KELHVHPPGM QYPDLQQDAR LKETLLFSAG KGFTDHQTQK SDYLELRAKL
   961  QTKPDYLEVL EKTTYRF

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SLITRK3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.46
Highest tissue expression: 13 nTPM

Expression across tissuesHPA

Tissue

fallopian tube: 13 nTPM
cerebral cortex: 9.3 nTPM
liver: 7.4 nTPM
endometrium: 6.7 nTPM
basal ganglia: 5.2 nTPM
seminal vesicle: 5.1 nTPM

Single-cell type

oligodendrocyte progenitor cells: 36 nCPM
brain inhibitory neurons: 20 nCPM
brain excitatory neurons: 17 nCPM
other brain neurons: 15 nCPM
retinal bipolar cells: 14 nCPM
smooth muscle cells: 11 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

hippocampal formation: 34 nTPM
cerebral cortex: 33 nTPM
cerebellum: 23 nTPM
basal ganglia: 22 nTPM
hypothalamus: 21 nTPM
amygdala: 21 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SLITRK3.

Disease | GeneticClinVar

1 pathogenic / likely-pathogenic of 113 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Intellectual disability

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.34
gnomAD pLI: 0.94
gnomAD missense Z: 0.59
DepMap mean gene effect: 0.01
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SLITRK3 as an antibody target. Whether an autoantibody or antibody against SLITRK3 could matter depends on whether native SLITRK3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SLITRK3 is annotated at the cell surface, where native SLITRK3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SLITRK3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...